BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Medigene AG (FSE: MDG1, Prime Standard, “Medigene”), a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, today announced that they have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer. The initial term of the collaboration is three years.
BioNTech and Medigene announce global collaboration to advance T cell receptor immunotherapies against cancer
February 21, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022